CO126 Effectiveness of Six PD-1/PD-L1 Inhibitors in Treatment of Patients with Advanced Squamous Non-Small Cell Lung Cancer: An Indirect Comparison and Partitioned Survival Model

Abstract

Since 2019, six PD-1/PD-L1 inhibitors (sugemalimab, sintilimab, pembrolizumab, camrelizumab, atezolizumab and tislelizumab) are already in or about to be launched in the Chinese market, but there are no head-to-head RCT studies reporting the comparative efficacy nor the long-term effectiveness. Therefore, this study aims to indirectly compare these six drugs and project to the final outcome in order to provide evidence for clinical decision and Chinese national reimbursement drug listing.